Quick Answer
Lineage Cell Therapeutics, Inc. reported Total Assets of $112.58 million for the year ending 2025.
- Lineage Cell Therapeutics, Inc. showed a decrease of -0.6% in Total Assets from 2024 to 2025.
- This data is from Lineage Cell Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $53.46 million | Q3 2011: $50.88 million | Q1 2012: $38.98 million | Q2 2012: $38.38 million | Q3 2012: $32.87 million | Q1 2013: $35.30 million | Q2 2013: $39.89 million | Q3 2013: $30.85 million | Q1 2014: $57.95 million | Q2 2014: $65.99 million | Q3 2014: $55.65 million | Q1 2015: $69.70 million | Q2 2015: $79.61 million | Q3 2015: $76.86 million | Q1 2016: $80.11 million | Q2 2016: $104.33 million | Q3 2016: $147.57 million | Q1 2017: $205.22 million | Q2 2017: $193.35 million | Q3 2017: $221.87 million | Q1 2018: $110.40 million | Q2 2018: $112.25 million | Q3 2018: $176.08 million | Q1 2019: $183.72 million | Q2 2019: $151.69 million | Q3 2019: $132.98 million | Q1 2020: $118.88 million | Q2 2020: $112.08 million | Q3 2020: $103.09 million | Q1 2021: $127.93 million | Q2 2021: $134.75 million | Q3 2021: $131.21 million | Q1 2022: $144.52 million | Q2 2022: $135.92 million | Q3 2022: $131.15 million | Q1 2023: $113.21 million | Q2 2023: $111.69 million | Q3 2023: $106.15 million | Q1 2024: $108.48 million | Q2 2024: $102.80 million | Q3 2024: $96.59 million | Q1 2025: $111.75 million | Q2 2025: $90.80 million | Q3 2025: $89.64 million.
- Over the full 16 years of available data (2010 to 2025), Lineage Cell Therapeutics, Inc.'s Total Assets has grown by 111.3%.
- Historical annual values: Fiscal year 2025: $112.58 million | Fiscal year 2024: $113.22 million | Fiscal year 2023: $101.02 million | Fiscal year 2022: $123.66 million | Fiscal year 2021: $174.55 million | Fiscal year 2020: $107.95 million | Fiscal year 2019: $125.48 million | Fiscal year 2018: $101.66 million | Fiscal year 2017: $173.24 million | Fiscal year 2016: $142.57 million | Fiscal year 2015: $94.66 million | Fiscal year 2014: $74.90 million | Fiscal year 2013: $57.73 million | Fiscal year 2012: $29.75 million | Fiscal year 2011: $45.83 million | Fiscal year 2010: $53.27 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: